found that low-dose gemcitabine (40 mg/kg, first day of the week) in combination with SRA737+ (100 mg/kg, first and second day of the week) and anti-PD-L1 (300 μg, third day of the week) combination therapy in the treatment of tumor-bearing mice had significantly better antitumor effects than single-agent or two-by-two dosing regimens. The gene discussed is CD274; the disease is neoplasm.